Screener / SEC EDGAR /CIK 0000939767 /10-K filed Feb 10, 2026, compared with Feb 11, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Exelixis, Inc. EXEL

Compare with peers Embed
Planned sales, announced before they happen

2 trading plans running, 25 Form 144 notices for $40.1M

10-Q, 10-K and Form 144

What EXEL's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Feb 12, 2024 to Jun 18, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Mary C. Beckerle
Board of Directors
Adopted 10b5-1 plan May 8, 2026 10-Q Aug 5, 2026
Brenda J. Hefti
Senior Vice President and General Counsel
Adopted 10b5-1 plan Nov 19, 2025 10-K Feb 10, 2026
What the company wrote
Brenda J. Hefti, our Senior Vice President and General Counsel, an officer for purposes of Section 16 of the Exchange Act, modified an existing 10b5-1 trading plan that was originally entered on February 26, 2025. Dr. Hefti’s modified trading plan provides for the sale of up to 30,202 shares of our common stock between February 18, 2026 and May 29, 2026. This modified trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities.
Jack L. Wyszomierski
member of our Board of Directors
Adopted 10b5-1 plan Nov 19, 2025 10-K Feb 10, 2026
What the company wrote
Jack L. Wyszomierski, a member of our Board of Directors, entered into a pre-arranged stock trading plan on November 19, 2025. Mr. Wyszomierski’s trading plan provides for the sale of up to 114,746 shares of our common stock (including shares obtained from the exercise of vested stock options covered by the trading plan) between February 18, 2026 and November 19, 2026. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities.
S. Gail Eckhardt
member of our Board of Directors
Adopted 10b5-1 plan Nov 11, 2025 10-K Feb 10, 2026
What the company wrote
S. Gail Eckhardt, a member of our Board of Directors, entered into a pre-arranged stock trading plan on November 11, 2025. Dr. Eckhardt’s trading plan provides for the sale of up to 13,668 shares of our common stock between February 13, 2026 and June 30, 2026. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities.
Amy C. Peterson
Executive Vice President, Product Development and Medical Affairs, and Chief Medical Officer
Adopted 10b5-1 plan Feb 13, 2025 10-Q May 13, 2025
What the company wrote
Amy C. Peterson, our Executive Vice President, Product Development and Medical Affairs, and Chief Medical Officer, an officer for purposes of Section 16 of the Exchange Act, entered into a pre-arranged stock trading plan on February 13, 2025. Ms. Peterson’s trading plan provides for the sale of up to 72,776 shares of our common stock (including shares obtained from the exercise of vested stock options covered by the trading plan) between May 16, 2025 and March 2, 2026. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities.
Jack L Wyszomierski
Board of Directors
Adopted 10b5-1 plan Nov 29, 2024 10-K Feb 11, 2025
S. Gail Eckhardt
Board of Directors
Adopted 10b5-1 plan Oct 30, 2024 10-K Feb 11, 2025
Patrick J. Haley
Executive Vice President, Commercial
Adopted 10b5-1 plan Aug 19, 2024 10-Q Oct 29, 2024
What the company wrote
Patrick J. Haley, our Executive Vice President, Commercial, an officer for purposes of Section 16 of the Exchange Act, entered into a pre-arranged stock trading plan on August 19, 2024. Mr. Haley’s trading plan provides for the sale of up to 72,207 shares of our common stock between November 18, 2024 and August 19, 2025. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities.
Jeffrey J. Hessekiel
Executive Vice President, General Counsel and Secretary
Adopted 10b5-1 plan Feb 28, 2024 10-Q Apr 30, 2024
What the company wrote
Jeffrey J. Hessekiel, our Executive Vice President, General Counsel and Secretary, an officer for purposes of Section 16 of the Exchange Act, entered into a pre-arranged stock trading plan on February 28, 2024. Mr. Hessekiel’s trading plan provides for the sale of up to 200,000 shares of our common stock (including shares obtained from the exercise of vested stock options covered by the trading plan) between May 29, 2024 and December 31, 2024. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities.
Jack L Wyszomierski
Board of Directors
Adopted 10b5-1 plan Feb 12, 2024 10-Q Apr 30, 2024
What the company wrote
Jack L Wyszomierski, a member of our Board of Directors, entered into a pre-arranged stock trading plan on February 12, 2024. Mr. Wyszomierski’s trading plan provides for the sale of up to 19,973 shares of our common stock (including shares obtained from the exercise of vested stock options covered by the trading plan) between May 13, 2024 and June 12, 2024. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities.
Alan M. Garber
Board of Directors
Adopted 10b5-1 plan Nov 8, 2023 10-K Feb 6, 2024
Patrick J. Haley
Executive Vice President, Commercial
Adopted 10b5-1 plan Aug 7, 2023 10-Q Nov 1, 2023
Dana T. Aftab
Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer
Adopted 10b5-1 plan May 25, 2023 10-Q Apr 30, 2024
What the company wrote
Dana T. Aftab, our Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer, an officer for purposes of Section 16 of the Exchange Act, entered into a pre-arranged stock trading plan on May 25, 2023, which was subsequently modified on February 27, 2024. As modified, Dr. Aftab’s trading plan provides for the sale of up to 194,656 shares of our common stock (including shares obtained from the exercise of vested stock options covered by the trading plan) between May 30, 2024 and September 30, 2025. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities.
Dana T. Aftab
Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer
Adopted 10b5-1 plan May 25, 2023 10-Q Aug 1, 2023
Show the other 6 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Aug 10, 2026 MARY BECKERLE
Director
9,812 $526K
Jun 1, 2026 Eckhardt Sue Gail
Director
9,812 $499K
Jun 1, 2026 JACK L WYSZOMIERSKI
Director
3,925 $198K
May 26, 2026 DANA T AFTAB
Officer
43,451 $2.2M
May 20, 2026 PATRICK JOSEPH HALEY
Officer
32,110 $1.6M
May 18, 2026 CHRISTOPHER J SENNER
Officer
34,901 $1.7M
May 18, 2026 BRENDA JOY HEFTI
Officer
6,625 $333K
May 14, 2026 BOMBORA RISE FOUNDATION
Family foundation of the CEO of EXEL.
100,000 $5.1M
May 7, 2026 MARY BECKERLE
Director
7,712 $374K
May 7, 2026 GEORGE H POSTE
Director
60,000 $2.7M
May 7, 2026 MARIA C FREIRE
Director
20,634 $949K
Feb 24, 2026 DANA T AFTAB
Officer
47,918 $2.1M
Feb 19, 2026 DANA T AFTAB
Officer
29,873 $1.3M
Feb 18, 2026 JULIE ANNE SMITH
Director
64,117 $2.8M
Feb 18, 2026 BRENDA JOY HEFTI
Officer
18,669 $822K
Feb 18, 2026 JACK L WYSZOMIERSKI
Director
99,574 $4.4M
Feb 17, 2026 JULIE ANNE SMITH
Director
42,422 $1.9M
Feb 17, 2026 CHRISTOPHER J SENNER
Officer
30,617 $1.3M
Feb 17, 2026 PATRICK JOSEPH HALEY
Officer
67,814 $3.0M
Feb 13, 2026 Eckhardt Sue Gail
Director
3,856 $165K
Feb 13, 2026 CHRISTOPHER J SENNER
Officer
34,278 $1.5M
Feb 13, 2026 ROBERT L OLIVER
Director
30,250 $1.3M
Feb 12, 2026 BOMBORA RISE FOUNDATION
Family foundation of the CEO of EXEL.
5,000 $216K
Dec 12, 2025 Haley Patrick J.
Officer, Member of immediate family of any of the foregoing
62,230 $2.6M
Nov 20, 2025 PATRICK JOSEPH HALEY
Officer
10,000 $421K
Show the other 17 notices

From the Form 144 XML filed with the SEC, since Nov 20, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/EXEL/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.